icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
UgyEYJQJfQSUe17N